Medicine Supply Notification: Discontinuation of lixisenatide (Lyxumia® ) 20micrograms/0.2ml solution for injection 3ml pre-filled disposable devices
Department of Health and Social Care (DHSC) has issued a medicine supply notification for the Discontinuation of lixisenatide (Lyxumia®) 20micrograms/0.2ml solution for injection 3ml pre-filled disposable devices
MSN/2023/088
Tier 2 – medium impact
Date of issue 21st September 2023
- Lixisenatide (Lyxumia®) 20micrograms/0.2ml solution for injection 3ml pre-filled disposable devices are being discontinued and stock will be exhausted by w/c 18th December 2023.
- Please refer to the Medicines Supply Tool on the Specialist Pharmacy Service (SPS) website for a supply update of other glucagon-like peptide receptor agonists (GLP-1 RA) and clinical guidance on alternative treatment options
- Information in the National Patient Safety Alert (NatPSA) on the shortage of GLP-1 receptor agonists issued on the 18th July 2023 can be used to guide management of patients switching from lixisenatide.
DHSC will continue to provide updates on GLP-1 RA’s stock availability on the Medicine Supply Tool and designated ‘Prescribing available GLP-1 receptor agonists’ page on the SPS website
A copy of this medicine supply notification, including further information for pharmacy teams, has been sent to all pharmacy NHS email addresses.
DHSC and NHSE/I have now launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.
The Tool also details any changes to resupply dates and updates to the entries.
To access the Tool you will need an NHS email address. Once set up and logged in, you will be able to access it online.
New shortages not listed on the SPS website, can be reported using our shortage reporting tool.
